Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system

Nicholas Jakowenko, Steffany Nguyen, Melanie Ruegger, Ashley Dinh, Eric Salazar, Kevin R. Donahue

Producción científica: Articlerevisión exhaustiva

26 Citas (Scopus)

Resumen

Background: Oral factor Xa inhibitors (FXaI) can be administered in fixed doses without the need for routine laboratory monitoring. Anti-Xa assays can estimate anticoagulant effect for specific FXaI's. The aim of this study was to characterize anti-Xa levels in patients taking apixaban or rivaroxaban with major bleeding events. Methods: Apixaban and rivaroxaban anti-Xa assays ordered within our hospital system from May 2016 to September 2019 were evaluated. The primary outcome was major bleeding events defined by International Society of Thrombosis and Haemostasis criteria. Median anti-Xa levels for each FXaI were calculated for those with and without major bleeding, as well as those who did and did not receive reversal agents. Results: A total of 606 anti-Xa levels were analyzed. There were 146 major bleeding events documented, with the most common site being intracranial (63%). Median anti-Xa levels in patients with and without major bleeding were similar, whereas those on apixaban therapy who received reversal agents typically had higher anti-Xa levels (73 ng/mL vs. 153 ng/mL, p = 0.0019). Factors significantly associated with increased odds of bleeding were an age > 80 years, inappropriately high dosing regimens, and modest anti-Xa levels (100–300 ng/mL) for rivaroxaban specifically. Conclusions: Older age and inappropriately high dosing regimens were associated with major bleeding in patients taking apixaban and rivaroxaban. Further investigation into the utility of anti-Xa levels for FXaI is warranted.

Idioma originalEnglish (US)
Páginas (desde-hasta)276-282
Número de páginas7
PublicaciónThrombosis Research
Volumen196
DOI
EstadoPublished - dic 2020
Publicado de forma externa

ASJC Scopus subject areas

  • Hematology

Huella

Profundice en los temas de investigación de 'Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system'. En conjunto forman una huella única.

Citar esto